LAE-32

LAE-32
Clinical data
Other namesLAE32; LAE; Lysergic acid ethylamide; d-Lysergic acid ethylamide; d-Ethyllysergamide
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
Identifiers
  • (8β)-N-Ethyl-6-methyl-9,10-didehydroergoline-8-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H21N3O
Molar mass295.386 g·mol−1
3D model (JSmol)
  • CCNC(=O)[C@@H]2C=C1c3cccc4[nH]cc(C[C@H]1N(C)C2)c34
  • InChI=1S/C18H21N3O/c1-3-19-18(22)12-7-14-13-5-4-6-15-17(13)11(9-20-15)8-16(14)21(2)10-12/h4-7,9,12,16,20H,3,8,10H2,1-2H3,(H,19,22)/t12-,16-/m1/s1 Y
  • Key:VEBWTGYUIBTVNR-MLGOLLRUSA-N Y
  (verify)

D-Lysergic acid ethylamide (LAE-32) is psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is reported to have some LSD-like effects but is weaker and shorter lasting, with an active dose reported to be between 0.5 and 1.4 mg.

It was studied by the CIA as part of Project MKULTRA. Documents published by the CIA under the Freedom of Information Act suggest it causes "a schizophrenia-like condition" but it allows people with schizophrenia to remain indifferent to their disorder. The drug has also been studied in psychedelic-assisted psychotherapy.

LAE-32 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.